Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Nov 29;52(5):1800897.
doi: 10.1183/13993003.00897-2018. Print 2018 Nov.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme

Timm Greulich  1 , Jan Chlumsky  2 , Marion Wencker  3 , Oliver Vit  4 , Michael Fries  5 , Thomas Chung  6 , Amgad Shebl  7 , Claus Vogelmeier  1 , Kenneth R Chapman  8 , Noel G McElvaney  9   10 ; RAPID Trial Group
Collaborators, Affiliations
Randomized Controlled Trial

Safety of biweekly α1-antitrypsin treatment in the RAPID programme

Timm Greulich et al. Eur Respir J. .

Abstract

Administration of 120 mg·kg−1 α1-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum

Trial registration: ClinicalTrials.gov NCT00261833 NCT00670007.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: T. Greulich reports personal fees from AstraZeneca and GSK (lecture fees), Boehringer-Ingelheim, Chiesi, CSL Behring and Novartis (lecture fees, advisory board and travel support), and Mundipharma (lecture fees and advisory board); and grants and personal fees from Grifols (AATD-Labor, lecture fees and travel support), all outside the submitted work. Conflict of interest: J. Chlumsky reports honoraria for lectures organised by CSL Behring, and for lectures organised by Boehringer Ingelheim, outside the submitted work. Conflict of interest: M. Wencker reports support from conresp as a consultant to CSL Behring, during the conduct of the study. Conflict of interest: O. Vit reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: M. Fries reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: T. Chung reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: A. Shebl reports support from CSL Behring, as employer and sponsor of the study. Conflict of interest: C. Vogelmeier reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols and Novartis; personal fees from CSL Behring, Chiesi, Menarini, Mundipharma, Teva and Cipla; and grants from Bayer-Schering, MSD and Pfizer, all outside the submitted work. Conflict of interest: K.R. Chapman reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Grifols, Sanofi, Genentech, Kamada, Roche and Novartis; grants from Baxter, GlaxoSmithKline, Amgen, Shire and Octapharma; personal fees from Merck; and the CIHR-GSK Research Chair in Respiratory Health Care Delivery, UHN, all during the conduct of the study. Conflict of interest: N.G. McElvaney reports research grants for carrying out the original RAPID and RAPID OLE studies from CSL Behring, during the conduct of the study; and personal fees from CSL Behring (advisory board), outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Patient flow, demographics and disease characteristics at baseline for patients who received at least one biweekly 120 mg·kg−1 α1-antitrypsin (α1-AT) infusion or matching placebo during RAPID (Randomised Trial of Augmentation Therapy in Alpha-1 Proteinase Inhibitor Deficiency)-Randomised Controlled Trial (RCT) or RAPID-Open Label Extension (OLE), and safety of α1-AT infusion sequences compared to placebo in RAPID-RCT occurring 7 days prior to and within 7 days after the administration of 120 mg·kg−1. Data are presented as mean±sd or n. Where only two data points were available, the individual data are shown in brackets. EAER: exposure-adjusted event rates (events per subject-years), parameter that takes into account all treatment-emergent adverse events (TEAEs) during the trial except the periods with unknown infusion volumes, which were omitted (64 out of 29 076 infusions); IAER: infusion-adjusted event rate (events per n infusion sequences), intra-individual comparison of TEAEs that includes individuals that have received 120 mg·kg−1 biweekly infusions. An infusion sequence consisted of a 60 mg·kg−1 weekly infusion or matching placebo followed by one or more infusions of biweekly 120 mg·kg−1 or matching placebo. In this analysis the number of TEAEs occurring within the 7-day period prior to a double-dose infusion while exposed to 60 mg·kg−1 or matching placebo was compared with those occurring in the 7-day period following the biweekly 120 mg·kg−1 infusion or matching placebo; Pi*Z: α1-AT deficiency; FEV1: forced expiratory volume in 1 s; PI: proteinase inhibitor; NA: not applicable. #: data obtained at baseline of RCT. : biweekly infusion sequences with α1-AT during RCT n=321 and during OLE n=563, total n=884. +: biweekly infusion sequences with placebo during RCT n=332. §: drug exposure for α1-AT group 60 mg weekly in RAPID-RCT was 158.20 subject-years; number of infusions (I) 8098; RAPID-OLE early treatment group 135.02 subject-years, I=6948; RAPID-OLE late treatment group 113.27 subject-years, I=5814. ƒ: drug exposure for α1-AT group 120 mg weekly in RAPID-RCT was 14.09 subject-years, I=333; RAPID-OLE early treatment group 12.50 subject-years, I=297; RAPID-OLE late treatment group 12.69 subject-years, I=303. ##: drug exposure for placebo group 120 mg weekly in RAPID-RCT was 134.92 subject-years, I=6845. ¶¶: drug exposure for placebo group 120 mg weekly in RAPID-RCT was 15.55 subject-years, I=374.
See this image and copyright information in PMC

References

    1. Greene CM, Marciniak SJ, Teckman J, et al. . α1-Antitrypsin deficiency. Nat Rev Dis Primers 2016; 2: 16051. - PubMed
    1. Gadek JE, Klein HG, Holland PV, et al. . Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68: 1158–1165. - PMC - PubMed
    1. Piras B, Ferrarotti I, Lara B, et al. . Clinical phenotypes of Italian and Spanish patients with α1-antitrypsin deficiency. Eur Respir J 2013; 42: 54–64. - PubMed
    1. Greulich T, Nell C, Herr C, et al. . Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015. Orphanet J Rare Dis 2016; 11: 75. - PMC - PubMed
    1. Chapman KR, Burdon JG, Piitulainen E, et al. . Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360–368. - PubMed

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources